Business Wire

Mundipharma Strengthens Position as a Leader in Biosimilars with Acquisition of Development Company Cinfa Biotech

Del

The Mundipharma global network of independent associated companies has today added development capabilities to its biosimilars platform with the purchase of biosimilars development company Cinfa Biotech.

The announcement sees the Mundipharma network (including NAPP Pharmaceuticals in the UK) gain immediate access to Pelmeg® (B12019), a biosimilar to Neulasta® (pegfilgrastim), which received CHMP recommendation for approval on 20th September 2018.

Alberto Martinez, President and CEO, Mundipharma International Ltd, “Our biosimilars platform is a key component of our growth strategy and today’s acquisition is the obvious next step in us ensuring we remain agile and innovative in the biosimilars space.

“We have successfully demonstrated our commercial excellence in biosimilars by building a market leading platform. Through our partnership with Celltrion on Remsima ® and Truxima ® we estimate savings for healthcare systems of approximately €330m 2 from launch to the end of 2017. By acquiring Cinfa Biotech we have now taken the first step in our plans to, not only expand our biosimilars footprint, but to develop future biosimilars which will continue to afford healthcare systems further savings and, in some cases, wider access for patients.”

Pelmeg® (originator Neulasta®3) is a pegylated version of granulocyte-colony stimulating factor (G-CSF) for the treatment of chemotherapy-induced neutropenia that works by stimulating the bone marrow to produce more neutrophils, thereby reducing the incidence of infection.

With a non-US market worth of $603mllion1 and originator patents already expired, pegfilgrastim biosimilars offer an exciting market opportunity.

Enrique Ordieres, President of Infarco the parent company of Cinfa Group, commented, “After having successfully developed and manufactured our first biosimilar, we strongly believe Mundipharma is best placed to take Pelmeg ® forward through the Cinfa Biotech acquisition. They have the pedigree and proven track record of launching biosimilars in Europe, have built strong partnerships with payers, hospital specialists and decision makers and have the deep local understanding of complex tender environments.”

-Ends-

Notes to editors:

About the Mundipharma network

The Mundipharma global network of privately-owned independent associated companies was founded in 1956 by doctors, and now operates in over 120 countries worldwide. We are focused on developing business partnerships to identify and accelerate meaningful technology across an increasingly diverse portfolio of therapy areas including respiratory, oncology, pain, and biosimilars. Consistent with our entrepreneurial heritage, we like to think we see what others don’t by challenging conventional wisdom and asking different and challenging questions. By working in partnership with all our stakeholders, the Mundipharma network develops medicines that create value for patients, payers and wider healthcare systems.

For more information please visit: www.mundipharma.com.

About Cinfa Biotech

Cinfa Biotech was created in 2013 as part of the Spanish Cinfa Group. The company conduct biosimilars development and manufacturing exclusively in Europe. Highest European quality standards based on strict guidelines and their specialist know-how are the key to their success in the global biosimilars market.

They currently have two product candidates in development including: Cinfa Biotech’s lead product candidate, pegfilgrastim, a biosimilar version of Neulasta® (INN: pegfilgrastim) to treat chemotherapy-induced neutropenia. Pegfilgrastim, a granulocyte colony-stimulating factor (G-CSF) receptor agonist, is used to stimulate bone marrow to produce more neutrophils in order to decrease the incidence of infection in patients undergoing chemotherapy.

About biosimilars

Biosimilar is a term used to describe officially approved subsequent versions of biopharmaceutical medicines that are made available by a different company following patent and exclusivity expiry on the original product. Biosimilars are classed as biologic medical products, which mean they contain an active drug substance that is comprised of, or derived from, a living organism.

Biosimilars are strictly regulated and need to demonstrate comparability to the previously approved reference product via a thorough development programme including quality, nonclinical and clinical data.

Remsima® (infliximab) and Truxima® (i.v. rituximab) are both registered trademarks of Celltrion, Inc. and are used under licence.

Neulasta® is a registered trademark of Amgen, Inc.

Pelmeg® is a registered trademark of Cinfa Biotech, S.L.

References:

1 Sales of Neulasta® in 2017: data from Amgen 2017 Fourth-quarter results (Global: $4,534 million. ROW: $603million). ROW sales: Available from: https://www.amgen.com/media/news-releases/2018/02/amgen-reports-fourth-quarter-and-full-year-2017-financial-results/
2 Figure based on Mundipharma data - Biosimilar savings: Truxima and Remsima net price vs originator list price x units or vials sold. Time periods are from launch, with data based on five markets for Remsima and six markets for Truxima through to year end 2017.
3Neulasta® patient information leaflet. Available from: https://www.medicines.org.uk/emc/product/6770/pil

Contact information

Mundipharma
For further information please contact:
Alison Dyson
T: +44 (0)1223 397346
alison.dyson@mundipharma.com
or email:
communications@mundipharma.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Malta and Austria Are Home to the World’s Best Investment Migration Programs23.10.2018 09:00Pressemelding

The Malta Individual Investor Program is the world’s top citizenship-by-investment program and the Austria Private Residence Program is the world’s top residence-by-investment program, according to the Global Residence and Citizenship Programs 2018–2019 report, released today by global residence and citizenship advisory firm Henley & Partners. Dr. Christian H. Kälin, an international immigration and citizenship law expert and Group Chairman of Henley & Partners, says the annual report provides a systematic analysis and comprehensive benchmarking of the world’s most important programs. “It’s an invaluable tool for anyone interested in alternative residence or citizenship as well as for the professionals like private bankers and lawyers who advise them. It also provides governments with a detailed picture of the broader investment migration industry landscape and where they fit it.” Malta is followed in the citizenship program ranking by Cyprus in 2nd place, Austria in 3rd place, and Ant

Temenos Ramps up AI Efforts to Power its Digital Banking Platform23.10.2018 08:30Pressemelding

Temenos (SIX: TEMN), the banking software company, today announced during the Machine Learning Panel at Sibos that it is increasing the development of Artificial Intelligence capabilities throughout its digital banking platform. The Temenos AI initiative will enable banks to offer personalized services to customers, augment users’ decisions with data-driven machine intelligence, and maximise straight-through-processing (STP) rates for financial transactions at reduced cost with limited or no human intervention. As part of this global initiative, Temenos has just launched a Centre of Excellence for Artificial Intelligence as its innovation engine. The Temenos AI Centre of Excellence will foster a collaborative ecosystem with Temenos’ banking clients and partners to help identify and validate use cases where AI could have an immediate impact on customer experience, as well as operational excellence, and hence improve the bottom line. Temenos’ pioneering initiative will involve injecting

ECAC EDS CB C3 Approval for Smiths Detection Technology23.10.2018 08:00Pressemelding

Smiths Detection has gained ECAC EDS CB C3 approval for the innovative HI-SCAN 6040 CTiX checkpoint scanner. This eliminates the need to remove electronic devices and liquids from hand luggage (subject to local authority guidelines) to make the process more passenger friendly. The HI-SCAN 6040 CTiX delivers the highest levels of security demanded by the new regulations, whilst optimizing checkpoint performance through improved productivity, a better passenger experience and lower operational costs. Removing the need to take out electronic devices and liquids from hand luggage means handling fewer trays which can significantly increase checkpoint throughput and the impressive 0.2m/s belt speed and low false alarm rate also speed up the process. “As the only technology meeting EDS CB C3 (and potentially future C4) standards, Computed Tomography (CT) is undoubtedly the way forward for checkpoint security,” commented Matt Clark, VP Technology & Product Development, Smiths Detection. “With

VIB 9–month profit before tax rises 176% YoY to VND 1,720 billion, Retail revenue increases 92% YoY23.10.2018 07:48Pressemelding

Vietnam International Bank (UPCoM: VIB) announced its financial statements of the first 9 months 2018 with positive results. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181023005507/en/ A clerk at VIB (Photo: Business Wire) Profit before tax grows 176% VIB reported profit before tax of VND 1,720 billion, up 176% year-on-year (YoY), equal to 86% of its full year target. The revenue increased by 48% YoY, in which interest income and non-interest income up 50% and 37% respectively; the latter accounted for 16% of total revenue and continued upward trend. The cost-to-income ratio (CIR) significantly dropped from 57% in 2017 to 48%. Provision expense in 9 months was lower than YoY in the context that VIB no longer has bad debts in VAMC. The return on equity ratio (ROE) reached 19.4%. The total asset of the bank reached over VND 132,500 billion, up 8% year-to-date; lending and deposits reached VND 95,200 billion and VND 89,200

Introducing The Continental Edge: The Easternmost Direct Interconnectivity Point Between Europe and the United States23.10.2018 07:00Pressemelding

Introducing the Continental Edge, the easternmost direct interconnection point between Europe and the United States. Four companies, focused on four key areas of services, have partnered to offer the first holistic solution that delivers best-of-breed colocation, connectivity, internet, and subsea cable solutions. The partnership is an amalgamation of companies brought to market collectivity by 1025Connect (for colocation); Aqua Comms (transatlantic subsea connectivity); DE-CIX (the leading Internet Peering Exchange), and Epsilon (a global network service provider providing on-demand SDN connectivity solutions). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181023005054/en/ The Continental Edge Map (Graphic: Business Wire) 1025Connect’s data center and colocation facilities serves as the central point where Aqua Comms' AEC-1 cable lands and Epsilon and DE-CIX platforms are available. Any customer connected to Epsilon’s lead

DataCo and SES Networks to Provide Broadband Network for APEC 201823.10.2018 06:50Pressemelding

Ahead of the 26th Asia-Pacific Economic Cooperation (APEC) forum taking place in Papua New Guinea, the PNG Government through its implementing agency, DataCo with the assistance of the Australian Government have chosen SES Networks to provide a managed data service delivering 6Gbps of high-bandwidth, low-latency connectivity to ensure the venues and all delegates have reliable, high-speed internet access during the conference from October to December 2018. SES announced that the service will utilise capacity from its O3b Medium Earth Orbit (MEO) satellite fleet to supplement existing capacity into Papua New Guinea (PNG) and will utilise existing DataCo infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181022006021/en/ DataCo and SES Networks to Provide Broadband Network for APEC 2018 (Photo: Business Wire) To provide additional connectivity to the nation, SES Networks has created a new core network for DataCo, f